Meiji Pharma Asia

Meiji Pharma Asia Pacific, operating primarily through Meiji Pharma (Singapore) Pte. Ltd., serves as the regional hub for the Japanese pharmaceutical giant Meiji Seika Pharma. The company focuses on the commercialization and distribution of a diverse portfolio including anti-infectives, central nervous system (CNS) drugs, and generic medications across the Asia-Pacific region. Key products include treatments for Parkinson's disease and various psychiatric disorders, alongside a strong historical foundation in antibiotics. The entity also manages regional business development, clinical trial coordination, and regulatory affairs to expand Meiji's footprint in emerging Asian markets.